Peter J. Weiden - Publications, H-index & Citations

Peter J. Weiden

state university of new york (suny) system

56H指数

258论文数

1.5W被引数

收录论文 67

发表时间

Lies and LAIs: why accuracy of information is the key to understanding the benefits and the resistance to using long-acting formulation

CNS SPECTRUMS

IF4.1

2025-12-19

OAAI

Weiden, Peter J.

Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia OASIS研究中的治疗模式与结局：一项关于精神分裂症长效注射剂的前瞻性观察研究

Neuropsychiatric Disease and Treatment

IF2.9

2025-09-23

OAAI

Peter J Weiden; Lauren N Strand; Michael J Doane; Christina Arevalo; James A McGrory; Eric D Achtyes; Philip D Harvey; John M Kane; Stephen R Saklad; Jeffrey Trotter; Dawn I Velligan

Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia 阿立哌唑一水合物作为每2个月一次的长效注射用抗精神病药治疗精神分裂症的药代动力学评估

Expert Opinion on Drug Metabolism & Toxicology

IF3.4

2025-09-16

PREAI

Craig Chepke; Peter J. Weiden; Leslie Citrome

Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia

SCHIZOPHRENIA

IF4.1

2022-12-03

OAAI

Correll, Christoph U.; Angelov, Angel S.; Miller, Andrew C.; Weiden, Peter J.; Brannan, Stephen K.

Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic

TRENDS IN PHARMACOLOGICAL SCIENCES

IF19.9

2022-12-01

OAAI

Yohn, Samantha E.; Weiden, Peter J.; Felder, Christian C.; Stahl, Stephen M.

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial

BMC PSYCHIATRY

IF3.6

2022-08-28

OAAI

Lysaker, Paul H.; Weiden, Peter J.; Sun, Xiaowu; O'Sullivan, Amy K.; McEvoy, Joseph P.

Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States

ADVANCES IN THERAPY

IF4

2022-07-18

OAAI

Martin, Amber; Bessonova, Leona; Hughes, Rachel; Doane, Michael J.; O'Sullivan, Amy K.; Snook, Kassandra; Cichewicz, Allie; Weiden, Peter J.; Harvey, Philip D.

Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study

BMC PSYCHIATRY

IF3.6

2021-10-08

OAAI

Nasrallah, Henry A.; Weiden, Peter J.; Walling, David P.; Du, Yangchun; Yao, Baiyun; Yagoda, Sergey; Claxton, Amy

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia

CNS DRUGS

IF7.4

2021-09-21

OAAI

Lauriello, John; Weiden, Peter J.; Gleeson, Carole D.; Shah, Ankit; Boulanger, Luke; Jariwala-Parikh, Krutika; Hedgeman, Elizabeth; O'Sullivan, Amy K.

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia 月桂酰阿立哌唑对精神分裂症患者健康相关生活质量的远期影响

BMC PSYCHIATRY

IF3.6

2021-03-24

OAAI

McEvoy, Joseph P.; Weiden, Peter J.; Lysaker, Paul H.; Sun, Xiaowu; O'Sullivan, Amy K.

Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals

CNS SPECTRUMS

IF4.1

2020-12-03

OAAI

Sommi, Roger W.; Rege, Bhaskar; Wehr, Angela; Faldu, Sejal; Du, Yangchun; Weiden, Peter J.

Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey

BMC PSYCHIATRY

IF3.6

2020-07-10

OAAI

Bessonova, Leona; Velligan, Dawn, I; Weiden, Peter J.; O'Sullivan, Amy K.; Yarlas, Aaron; Bayliss, Martha; Baranwal, Nishtha; Rychlec, Kaitlin; Carpenter-Conlin, Julia; Doane, Michael J.; Sajatovic, Martha

Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study

CNS DRUGS

IF7.4

2020-07-03

OAAI

Weiden, Peter J.; Du, Yangchun; von Moltke, Lisa; Wehr, Angela; Hard, Marjie; Marandi, Morteza; Walling, David P.

Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia

AMERICAN JOURNAL OF PSYCHIATRY

IF14.7

2019-06-01

OAAI

Martin, William F.; Correll, Christoph U.; Weiden, Peter J.; Jiang, Ying; Pathak, Sanjeev; DiPetrillo, Lauren; Silverman, Bernard L.; Ehrich, Elliot W.

Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study

SCHIZOPHRENIA RESEARCH

IF3.5

2019-06-01

OAAI

Miller, Brian J.; Claxton, Amy; Du, Yangchun; Weiden, Peter J.; Potkin, Steven G.

Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia

CNS SPECTRUMS

IF4.1

2019-05-21

OAAI

Jain, Rakesh; Meyer, Jonathan; Wehr, Angela; Rege, Bhaskar; von Moltke, Lisa; Weiden, Peter J.